Cargando…
miR-4759 suppresses breast cancer through immune checkpoint blockade
Programmed cell death protein 1 (PD-1)/ programmed cell death protein ligand 1 (PD-L1) is the key immune checkpoint governing evasion of advanced cancer from immune surveillance. Immuno-oncology (IO) therapy targeting PD-1/PD-L1 with traditional antibodies is a promising approach to multiple cancer...
Autores principales: | Lin, You-Zhe, Liu, Shu-Hsuan, Wu, Wan-Rong, Shen, Yi-Chun, Wang, Yuan-Liang, Liao, Chien-Ching, Lin, Pei-Le, Chang, Han, Liu, Liang-Chih, Cheng, Wei-Chung, Wang, Shao-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718579/ https://www.ncbi.nlm.nih.gov/pubmed/35024096 http://dx.doi.org/10.1016/j.csbj.2021.12.020 |
Ejemplares similares
-
Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
por: Lin, Chia-Yi, et al.
Publicado: (2023) -
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Chu, Pei-Yi, et al.
Publicado: (2021) -
LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016) -
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020) -
Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer
por: Chen, Mei‐Chih, et al.
Publicado: (2023)